Share This Page
Drug Price Trends for NDC 60219-2651
✉ Email this page to a colleague
Average Pharmacy Cost for 60219-2651
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SILDENAFIL 10 MG/ML ORAL SUSP | 60219-2651-01 | 0.51481 | ML | 2025-12-17 |
| SILDENAFIL 10 MG/ML ORAL SUSP | 60219-2651-01 | 0.56725 | ML | 2025-11-19 |
| SILDENAFIL 10 MG/ML ORAL SUSP | 60219-2651-01 | 0.60995 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60219-2651
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 60219-2651
Introduction
The pharmaceutical landscape is dynamic, marked by rapid innovations, regulatory shifts, and evolving pricing mechanisms. NDC 60219-2651 represents a specific drug within this complex ecosystem. Conducting a comprehensive market analysis and formulating price projections for this NDC involves understanding its therapeutic category, competitive positioning, manufacturing status, regulatory environment, and payer landscape. This report synthesizes these aspects to guide stakeholders in making informed decisions.
Product Overview and Therapeutic Indication
NDC 60219-2651 corresponds to [Product Name], a [drug class, e.g., biologic, small molecule, biosimilar, etc.], approved by the FDA for [indication, e.g., treatment of [disease/condition]]. Designed to address [specific unmet medical needs or prevalent conditions], this product targets a sizable patient population, with an increasing prevalence due to [demographic shifts, disease epidemiology, or rising diagnosis rates].
Its unique mechanism of action, [description of benefits or differentiators, e.g., improved efficacy, safety profile, or dosing convenience], enhances its competitive positioning in the market.
Market Dynamics and Competitive Landscape
Market Size and Growth Drivers
The global market for [indication/therapeutic class] is projected to expand at a CAGR of [X]% through [year], driven by factors such as [advances in diagnostics, increasing prevalence, aging populations, or new treatment guidelines]. In the United States, the addressable market's valuation is estimated at $[X] billion as of [most recent year], with specific growth attributed to expanded indications and increased treatment adoption.
Competitive Positioning
NDC 60219-2651 faces competition from:
- Brand-name counterparts: These often hold substantial market share due to established efficacy and physician familiarity.
- Biosimilars: Emerging biosimilars aim to reduce costs and expand access, increasing price competition.
- New entrants: Innovative therapies or combination regimens could erode market share over time.
The product’s differentiation, safety profile, and pricing strategies critically impact its competitive edge.
Market Penetration and Patient Access
Reimbursement policies, insurance coverage, and formulary placements play a vital role in market penetration. The inclusion of [product name] in national and regional formularies, along with Tier placement, influences patient access and revenue potential.
Furthermore, post-marketing surveillance and physician education can accelerate adoption rates, especially if the product demonstrates clear clinical advantages.
Regulatory and Reimbursement Environment
Regulatory Status
NDC 60219-2651 is FDA approved, with indications aligned with unmet needs in [medical condition]. Ongoing post-approval studies and potential supplemental indications could impact future market scope.
Reimbursement Policies
Reimbursement frameworks are evolving, with payers increasingly emphasizing value-based care. Payer coverage policies, prior authorization requirements, and negotiated discounts directly influence the product’s market penetration and profitability.
Pricing Landscape and Projections
Current Pricing
As of [most recent data point], the average wholesale price (AWP) for [product name] stands at $[X] per [dose/administration]. Manufacturer discounts, managed care negotiations, and direct-to-consumer pricing strategies influence the net prices paid.
Historical Price Trends
Over the past [X years], similar therapies experienced [price increases, stability, or reductions], often driven by:
- Increased manufacturing costs
- Inflation adjustments
- Market launch of biosimilars
- Policy-driven price controls
Projected Price Trends
Considering the current landscape, the following projections are made:
| Year | Expected Average Price | Drivers / Rationale |
|---|---|---|
| [Year] | $[X] | Stable, influenced by market competition and payer negotiations |
| [Year + 1] | $[X+Y] | Potential modest increase due to inflation and value-based pricing initiatives |
| [Year + 2] | $[X+Z] | Possible stabilization with biosimilar entry or price caps |
Note: Biosimilar competition could introduce downward pressure, potentially reducing prices by [X]% over the next [Y] years. Conversely, if the product secures breakthrough therapy or expanded indications, prices may stabilize or even increase.
Impact of Biosimilars and Generic Alternatives
The introduction of biosimilars is poised to significantly reshape pricing dynamics:
- Timeline: Expected biosimilar approval and launch within [X] years.
- Price erosion: Biosimilars can reduce originator prices by [Y]%, influencing overall market revenues.
- Market share shifts: Biosims tend to rapidly capture [Z]% of their reference product’s market share within [Y] years post-launch.
The company's strategic response, such as lifecycle management and value demonstration, is essential in maintaining revenue streams.
Strategic Opportunities and Risks
Opportunities
- Expanded indications: Pursuing additional approved uses can enhance market volume.
- Enhanced value propositions: Demonstrating superior efficacy or safety can justify premium pricing.
- Partnerships and collaborations: Partnering with payers or advocacy groups can improve market access and acceptance.
Risks
- Pricing pressures: Increased competition and biosimilar entries threaten sustained pricing.
- Regulatory hurdles: Delays in approvals or unfavorable decisions can impact market entry.
- Market saturation: High adoption rates may plateau, limiting growth potential.
Key Takeaways
- Market growth is robust for therapeutics targeting [condition], driven by demographic trends and unmet medical needs.
- Pricing strategies are evolving, with potential increases offset by biosimilar competition and payer discounts.
- Market entry timing and differentiation are critical to maximizing revenue, especially with imminent biosimilar pressures.
- Expanded indications and value-based care models represent growth avenues.
- Manufacturers must monitor regulatory developments and payer policies closely to adapt pricing and market access strategies effectively.
Conclusion
The analysis of NDC 60219-2651 indicates a competitive yet lucrative market environment, contingent upon strategic positioning against biosimilar entrants and evolving payer landscape. Price projections suggest stability with potential modest increases, tempered by competitive dynamics. Stakeholders must prioritize differentiation, lifecycle management, and payer engagement to optimize market presence and revenue potential.
FAQs
-
What is the primary indication for NDC 60219-2651?
It is approved for [specific indication], targeting [patient population/disease]. -
How does biosimilar competition impact pricing for this drug?
Biosimilars typically drive down prices through competition, potentially reducing originator prices by [Y]%, while eroding market share. -
What factors influence future price trends for this drug?
Key factors include biosimilar market entry, regulatory changes, reimbursement policies, and clinical value demonstration. -
Are there opportunities to expand the market for this drug?
Yes, pursuing additional indications and demonstrating superior clinical efficacy could broaden adoption and justify premium pricing. -
What is the outlook for reimbursement policies affecting this product?
Increasing emphasis on value-based care and cost containment may lead to stricter reimbursement criteria, influencing pricing and access strategies.
References
[1] Industry Reports on Biosimilars and Market Trends (2022-2023)
[2] FDA Approvals Database (2023)
[3] IQVIA Market Insights (2022)
[4] CMS and Payer Policy Updates (2023)
[5] Competitive Intelligence Reports (2022)
Note: Replace bracketed placeholders with specific data upon access.
More… ↓
